LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
企業コードLIVN
会社名LivaNova PLC
上場日Oct 19, 2015
最高経営責任者「CEO」Makatsaria (Vladimir A)
従業員数2900
証券種類Ordinary Share
決算期末Oct 19
本社所在地20 Eastbourne Terrace
都市LONDON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United Kingdom
郵便番号W2 6LG
電話番号442033250662
ウェブサイトhttps://www.livanova.com/
企業コードLIVN
上場日Oct 19, 2015
最高経営責任者「CEO」Makatsaria (Vladimir A)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし